A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|Colonic Neoplasms|Lung Neoplasms|Pancreatic Neoplasms|Stomach Neoplasms
Interventions: DRUG: Rituximab
Sponsor: National Cancer Institute (NCI)